Your browser doesn't support javascript.
loading
Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
Tay, S K; Hsu, T-Y; Pavelyev, A; Walia, A; Kulkarni, A S.
Afiliación
  • Tay SK; Department of Obstetrics & Gynaecology, Singapore General Hospital, Singapore.
  • Hsu TY; Medical Affairs, MSD Pharma (Singapore) Pte. Ltd., Singapore.
  • Pavelyev A; HCL America, Sunnyvale, CA, USA.
  • Walia A; Department of Medical Affairs, MSD International GmbH (Singapore Branch), Singapore.
  • Kulkarni AS; Center for Observational and Real World Evidence, Merck & Co., Inc., Kenilworth, NJ, USA.
BJOG ; 125(4): 478-486, 2018 Mar.
Article en En | MEDLINE | ID: mdl-29266694
ABSTRACT

OBJECTIVE:

To examine the epidemiological and economic impact of a nine-valent (nonavalent) human papillomavirus (HPV) 6/11/16/18/31/33/45/52/58 vaccine programme for young teenagers in Singapore.

DESIGN:

Mathematical modelling.

SETTING:

Pharmaco-economic simulation projection. POPULATION Singapore demography.

METHODS:

Clinical, epidemiological and financial data from Singapore were used in a validated HPV transmission dynamic mathematical model to analyse the impact of nonavalent HPV vaccination over quadrivalent and bivalent vaccines in a school-based 2-dose vaccination for 11- to 12-year-old girls in the country. The model assumed routine cytology screening in the current rate (50%) and vaccine coverage rate of 80%. MAIN OUTCOME

MEASURES:

Changes over a 100-year time period in the incidence and mortality rates of cervical cancer, case load of genital warts, and incremental cost-effectiveness ratio (ICER).

RESULTS:

Compared with bivalent and quadrivalent HPV vaccination programmes, nonavalent HPV universal vaccination resulted in an additional reduction of HPV31/33/45/52/58 related CIN1 of 40.5%, CIN 2/3 of 35.4%, cervical cancer of 23.5%, and cervical cancer mortality of 20.2%. Compared with bivalent HPV vaccination, there was an additional reduction in HPV-6/11 related CIN1 of 75.7%, and genital warts of 78.9% in women and 73.4% in men. Over the 100 years, after applying a discount of 3%, disease management cost will be reduced by 32.5% (versus bivalent) and 7.5% (versus quadrivalent). The incremental cost-effectiveness ratio (ICER) per quality-adjusted life-year gained was SGD 929 compared with bivalent vaccination and SGD 9864 compared with quadrivalent vaccination.

CONCLUSION:

Universal two-dose nonavalent HPV vaccination for 11- to 12-year-old adolescent women is very cost-effective in Singapore. TWEETABLE ABSTRACT Nonavalent HPV vaccination of 11- to 12-year-old girls is cost-effective in Singapore.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Cuello Uterino / Programas de Inmunización / Infecciones por Papillomavirus / Vacunas contra Papillomavirus Tipo de estudio: Health_economic_evaluation / Incidence_studies / Prognostic_studies Aspecto: Patient_preference Límite: Child / Female / Humans País/Región como asunto: Asia Idioma: En Revista: BJOG Asunto de la revista: GINECOLOGIA / OBSTETRICIA Año: 2018 Tipo del documento: Article País de afiliación: Singapur

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias del Cuello Uterino / Programas de Inmunización / Infecciones por Papillomavirus / Vacunas contra Papillomavirus Tipo de estudio: Health_economic_evaluation / Incidence_studies / Prognostic_studies Aspecto: Patient_preference Límite: Child / Female / Humans País/Región como asunto: Asia Idioma: En Revista: BJOG Asunto de la revista: GINECOLOGIA / OBSTETRICIA Año: 2018 Tipo del documento: Article País de afiliación: Singapur